Trial reportNature communications2026
Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial.
Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04744649 (Efficacy and Safety of Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Open-label, Phase 2 Randomised Controlled Trial (NICE Trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this phase 2 trial (NCT04744649), 17 patients with locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma (cT2-4aN1-3M0) received four cycles neoadjuvant toripalimab plus capecitabine/oxaliplatin. The primary endpoint was major pathological response; secondary endpoints included pathological complete response, R0 resection, adverse events, event-free survival, overall survival, and tumor microenvironment. Paired pre-/post-treatment tissues were assessed by immunofluorescence. 16 patients underwent curative resection; 1 declined surgery. Major pathological response, pathological complete response, and ypN0 were 37.5% (6/16, 95% CI 0.15-0.65), 25.0% (4/16, 95% CI 0.07-0.52), and 81.3% (13/16, 95% CI 0.54-0.96), respectively. Major pathological response was more frequent in patients with programmed death ligand 1 ≥20 (57.1%, 95%CI 0.18-0.90). Major pathological response was associated with higher pretreatment CD8⁺ T-cell density. 35.3% reported grade 3-4 adverse events. These findings suggest that neoadjuvant immunochemotherapy demonstrated favorable efficacy with a manageable safety profile in Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.